Tenaya Therapeutics, Inc. (TNYA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 19.02M USD | Liabilities, Current |
| Cash and equivalents | 78.08M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 371.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $19.02M | $78.08M | (m) | $371.00K | (m) | (m) |
| 2026-03-31 | (m) | $16.78M | $80.89M | (m) | $10.63M | (m) | (m) |
| 2025-12-31 | (m) | $15.44M | $100.55M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $13.21M | $56.31M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $12.65M | $62.67M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $14.15M | $53.77M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $15.97M | $4.32M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $16.18M | $8.23M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $16.71M | $58.13M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $19.16M | $59.30M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $22.73M | $45.68M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $19.38M | $82.15M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $20.92M | $75.56M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $19.30M | $72.54M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $24.25M | $95.27M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $17.72M | $34.49M | $114.96M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $18.74M | $31.01M | $149.91M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $19.09M | $25.97M | $184.48M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $21.77M | $38.13M | $213.17M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $13.69M | $117.08M | $163.39M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $9.80M | $111.89M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $128.44M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $5.04M | $128.53M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $61.34M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $40.34M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |